2019
DOI: 10.1111/exd.13920
|View full text |Cite
|
Sign up to set email alerts
|

A potential link between desmoglein 3 and epidermal growth factor receptor in oral squamous cell carcinoma and its effect on cetuximab treatment efficacy

Abstract: Desmoglein (DSG) 3 is overexpressed in oral squamous cell carcinoma (OSCC). Epidermal growth factor receptor (EGFR) inhibitor cetuximab is widely used for OSCC treatment. Several evidences suggest a correlation between DSG3 and EGFR in epidermal keratinocytes. EGFR inhibition has been shown to enhance cell‐cell adhesion and induce terminal differentiation in epidermal cells. Thus, here we investigated the DSG3‐EGFR interaction in OSCC and its effect on cetuximab treatment. Cell lines established from the prima… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 27 publications
0
4
0
Order By: Relevance
“…Interlukin-6 is a multifunctional cytokine having a wide range of immunological activities, and it is also a potential mediator in the cancer development. It is known to promote proliferation of OSCC cell lines and on the other hand stabilizes the antibody inhibited growth in vivo (Minabe et al, 2019). OSCC patients were examined to determine the expression of IL-6 and IL-6 receptor.…”
Section: Resultsmentioning
confidence: 99%
“…Interlukin-6 is a multifunctional cytokine having a wide range of immunological activities, and it is also a potential mediator in the cancer development. It is known to promote proliferation of OSCC cell lines and on the other hand stabilizes the antibody inhibited growth in vivo (Minabe et al, 2019). OSCC patients were examined to determine the expression of IL-6 and IL-6 receptor.…”
Section: Resultsmentioning
confidence: 99%
“…In OSCC, there is a potential link between DSG3 and EGFR, and the expression of DSG3 was significantly increased after treatment with cetuximab, an inhibitor of EGFR. Furthermore, high calcium-associated DSG3 induction enhanced the efficacy of cetuximab in cetuximab-low-sensitive cell lines by up to 23% [92]. Differential expression analysis in oral leukoplakia (OL) tissues and OSCC tissues showed mild to severe loss of the DSG3/γcatenin complex and a transition from membranous to cytoplasmic expression, resulting in perinuclear aggregation, which was directly related to the grade of dysplasia [95].…”
Section: Desmosomal Cadherins Act As a Suppressor In Hncmentioning
confidence: 99%
“…[ 32 ] Studies have shown a potential link between DSG3 and EGFR in OSCC as the expression of DSG3 was increased after the treatment with cetuximab, an inhibitor of EGFR. [ 33 ]…”
Section: Introductionmentioning
confidence: 99%